Table of Content

1 Market Overview of Neuraminidase Inhibitors Drug
1.1 Neuraminidase Inhibitors Drug Market Overview
1.1.1 Neuraminidase Inhibitors Drug Product Scope
1.1.2 Neuraminidase Inhibitors Drug Market Status and Outlook
1.2 Global Neuraminidase Inhibitors Drug Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Neuraminidase Inhibitors Drug Market Size by Region (2018-2029)
1.4 Global Neuraminidase Inhibitors Drug Historic Market Size by Region (2018-2024)
1.5 Global Neuraminidase Inhibitors Drug Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Neuraminidase Inhibitors Drug Market Size (2018-2029)
1.6.1 North America Neuraminidase Inhibitors Drug Market Size (2018-2029)
1.6.2 Europe Neuraminidase Inhibitors Drug Market Size (2018-2029)
1.6.3 Asia-Pacific Neuraminidase Inhibitors Drug Market Size (2018-2029)
1.6.4 Latin America Neuraminidase Inhibitors Drug Market Size (2018-2029)
1.6.5 Middle East & Africa Neuraminidase Inhibitors Drug Market Size (2018-2029)
2 Neuraminidase Inhibitors Drug Market by Type
2.1 Introduction
2.1.1 Oseltamivir
2.1.2 Zanamivir
2.1.3 Peramivir
2.1.4 Laninamivir
2.2 Global Neuraminidase Inhibitors Drug Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Type (2018-2024)
2.2.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Neuraminidase Inhibitors Drug Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Neuraminidase Inhibitors Drug Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Neuraminidase Inhibitors Drug Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Neuraminidase Inhibitors Drug Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Neuraminidase Inhibitors Drug Revenue Breakdown by Type (2018-2029)
3 Neuraminidase Inhibitors Drug Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacy
3.1.2 Retail Pharmacy
3.1.3 Online Pharmacy
3.1.4 Others
3.2 Global Neuraminidase Inhibitors Drug Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Application (2018-2024)
3.2.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Neuraminidase Inhibitors Drug Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Neuraminidase Inhibitors Drug Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Neuraminidase Inhibitors Drug Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Neuraminidase Inhibitors Drug Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Neuraminidase Inhibitors Drug Revenue Breakdown by Application (2018-2029)
4 Neuraminidase Inhibitors Drug Competition Analysis by Players
4.1 Global Neuraminidase Inhibitors Drug Market Size by Players (2018-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2022)
4.3 Date of Key Players Enter into Neuraminidase Inhibitors Drug Market
4.4 Global Top Players Neuraminidase Inhibitors Drug Headquarters and Area Served
4.5 Key Players Neuraminidase Inhibitors Drug Product Solution and Service
4.6 Competitive Status
4.6.1 Neuraminidase Inhibitors Drug Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche Neuraminidase Inhibitors Drug Products, Services and Solutions
5.1.4 Roche Neuraminidase Inhibitors Drug Revenue (US$ Million) & (2018-2024)
5.1.5 Roche Recent Developments
5.2 GSK
5.2.1 GSK Profile
5.2.2 GSK Main Business
5.2.3 GSK Neuraminidase Inhibitors Drug Products, Services and Solutions
5.2.4 GSK Neuraminidase Inhibitors Drug Revenue (US$ Million) & (2018-2024)
5.2.5 GSK Recent Developments
5.3 Gilead Sciences
5.3.1 Gilead Sciences Profile
5.3.2 Gilead Sciences Main Business
5.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Products, Services and Solutions
5.3.4 Gilead Sciences Neuraminidase Inhibitors Drug Revenue (US$ Million) & (2018-2024)
5.3.5 Daiichi Sankyo Recent Developments
5.4 Daiichi Sankyo
5.4.1 Daiichi Sankyo Profile
5.4.2 Daiichi Sankyo Main Business
5.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Products, Services and Solutions
5.4.4 Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue (US$ Million) & (2018-2024)
5.4.5 Daiichi Sankyo Recent Developments
5.5 AstraZeneca
5.5.1 AstraZeneca Profile
5.5.2 AstraZeneca Main Business
5.5.3 AstraZeneca Neuraminidase Inhibitors Drug Products, Services and Solutions
5.5.4 AstraZeneca Neuraminidase Inhibitors Drug Revenue (US$ Million) & (2018-2024)
5.5.5 AstraZeneca Recent Developments
5.6 Pfizer
5.6.1 Pfizer Profile
5.6.2 Pfizer Main Business
5.6.3 Pfizer Neuraminidase Inhibitors Drug Products, Services and Solutions
5.6.4 Pfizer Neuraminidase Inhibitors Drug Revenue (US$ Million) & (2018-2024)
5.6.5 Pfizer Recent Developments
5.7 Teva
5.7.1 Teva Profile
5.7.2 Teva Main Business
5.7.3 Teva Neuraminidase Inhibitors Drug Products, Services and Solutions
5.7.4 Teva Neuraminidase Inhibitors Drug Revenue (US$ Million) & (2018-2024)
5.7.5 Teva Recent Developments
5.8 Bristol-Myers Squibb
5.8.1 Bristol-Myers Squibb Profile
5.8.2 Bristol-Myers Squibb Main Business
5.8.3 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Products, Services and Solutions
5.8.4 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Revenue (US$ Million) & (2018-2024)
5.8.5 Bristol-Myers Squibb Recent Developments
5.9 Sun Pharmaceutical
5.9.1 Sun Pharmaceutical Profile
5.9.2 Sun Pharmaceutical Main Business
5.9.3 Sun Pharmaceutical Neuraminidase Inhibitors Drug Products, Services and Solutions
5.9.4 Sun Pharmaceutical Neuraminidase Inhibitors Drug Revenue (US$ Million) & (2018-2024)
5.9.5 Sun Pharmaceutical Recent Developments
6 North America
6.1 North America Neuraminidase Inhibitors Drug Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Neuraminidase Inhibitors Drug Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Neuraminidase Inhibitors Drug Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Neuraminidase Inhibitors Drug Market Dynamics
11.1 Neuraminidase Inhibitors Drug Industry Trends
11.2 Neuraminidase Inhibitors Drug Market Drivers
11.3 Neuraminidase Inhibitors Drug Market Challenges
11.4 Neuraminidase Inhibitors Drug Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Neuraminidase Inhibitors Drug Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
Table 2. Global Neuraminidase Inhibitors Drug Market Size by Region (2018-2024) & (US$ Million)
Table 3. Global Neuraminidase Inhibitors Drug Market Size Share by Region (2018-2024)
Table 4. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 5. Global Neuraminidase Inhibitors Drug Forecasted Market Size Share by Region (2024-2029)
Table 6. Global Neuraminidase Inhibitors Drug Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
Table 7. Global Neuraminidase Inhibitors Drug Market Size by Type (2018-2024) & (US$ Million)
Table 8. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2018-2024)
Table 9. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 10. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2024-2029)
Table 11. North America Neuraminidase Inhibitors Drug Revenue by Type (2018-2024) & (US$ Million)
Table 12. North America Neuraminidase Inhibitors Drug Revenue by Type (2024-2029) & (US$ Million)
Table 13. Europe Neuraminidase Inhibitors Drug Revenue by Type (2018-2024) & (US$ Million)
Table 14. Europe Neuraminidase Inhibitors Drug Revenue by Type (2024-2029) & (US$ Million)
Table 15. Asia-Pacific Neuraminidase Inhibitors Drug Revenue by Type (2018-2024) & (US$ Million)
Table 16. Asia-Pacific Neuraminidase Inhibitors Drug Revenue by Type (2024-2029) & (US$ Million)
Table 17. Latin America Neuraminidase Inhibitors Drug Revenue by Type (2018-2024) & (US$ Million)
Table 18. Latin America Neuraminidase Inhibitors Drug Revenue by Type (2024-2029) & (US$ Million)
Table 19. Middle East and Africa Neuraminidase Inhibitors Drug Revenue by Type (2018-2024) & (US$ Million)
Table 20. Middle East and Africa Neuraminidase Inhibitors Drug Revenue by Type (2024-2029) & (US$ Million)
Table 21. Global Neuraminidase Inhibitors Drug Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
Table 22. Global Neuraminidase Inhibitors Drug Market Size by Application (2018-2024) & (US$ Million)
Table 23. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2018-2024)
Table 24. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 25. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2024-2029)
Table 26. North America Neuraminidase Inhibitors Drug Revenue by Application (2018-2024) & (US$ Million)
Table 27. North America Neuraminidase Inhibitors Drug Revenue by Application (2024-2029) & (US$ Million)
Table 28. Europe Neuraminidase Inhibitors Drug Revenue by Application (2018-2024) & (US$ Million)
Table 29. Europe Neuraminidase Inhibitors Drug Revenue by Application (2024-2029) & (US$ Million)
Table 30. Asia-Pacific Neuraminidase Inhibitors Drug Revenue by Application (2018-2024) & (US$ Million)
Table 31. Asia-Pacific Neuraminidase Inhibitors Drug Revenue by Application (2024-2029) & (US$ Million)
Table 32. Latin America Neuraminidase Inhibitors Drug Revenue by Application (2018-2024) & (US$ Million)
Table 33. Latin America Neuraminidase Inhibitors Drug Revenue by Application (2024-2029) & (US$ Million)
Table 34. Middle East and Africa Neuraminidase Inhibitors Drug Revenue by Application (2018-2024) & (US$ Million)
Table 35. Middle East and Africa Neuraminidase Inhibitors Drug Revenue by Application (2024-2029) & (US$ Million)
Table 36. Global Neuraminidase Inhibitors Drug Revenue (US$ Million) by Players (2018-2024)
Table 37. Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2018-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2022)
Table 39. Date of Key Players Enter into Neuraminidase Inhibitors Drug Market
Table 40. Global Neuraminidase Inhibitors Drug Key Players Headquarters and Area Served
Table 41. Neuraminidase Inhibitors Drug Product Solution and Service
Table 42. Global Neuraminidase Inhibitors Drug Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Roche Basic Information List
Table 45. Roche Description and Business Overview
Table 46. Roche Neuraminidase Inhibitors Drug Products, Services and Solutions
Table 47. Revenue (US$ Million) in Neuraminidase Inhibitors Drug Business of Roche (2018-2024)
Table 48. Roche Recent Developments
Table 49. GSK Basic Information List
Table 50. GSK Description and Business Overview
Table 51. GSK Neuraminidase Inhibitors Drug Products, Services and Solutions
Table 52. Revenue (US$ Million) in Neuraminidase Inhibitors Drug Business of GSK (2018-2024)
Table 53. GSK Recent Developments
Table 54. Gilead Sciences Basic Information List
Table 55. Gilead Sciences Description and Business Overview
Table 56. Gilead Sciences Neuraminidase Inhibitors Drug Products, Services and Solutions
Table 57. Revenue (US$ Million) in Neuraminidase Inhibitors Drug Business of Gilead Sciences (2018-2024)
Table 58. Gilead Sciences Recent Developments
Table 59. Daiichi Sankyo Basic Information List
Table 60. Daiichi Sankyo Description and Business Overview
Table 61. Daiichi Sankyo Neuraminidase Inhibitors Drug Products, Services and Solutions
Table 62. Revenue (US$ Million) in Neuraminidase Inhibitors Drug Business of Daiichi Sankyo (2018-2024)
Table 63. Daiichi Sankyo Recent Developments
Table 64. AstraZeneca Basic Information List
Table 65. AstraZeneca Description and Business Overview
Table 66. AstraZeneca Neuraminidase Inhibitors Drug Products, Services and Solutions
Table 67. Revenue (US$ Million) in Neuraminidase Inhibitors Drug Business of AstraZeneca (2018-2024)
Table 68. AstraZeneca Recent Developments
Table 69. Pfizer Basic Information List
Table 70. Pfizer Description and Business Overview
Table 71. Pfizer Neuraminidase Inhibitors Drug Products, Services and Solutions
Table 72. Revenue (US$ Million) in Neuraminidase Inhibitors Drug Business of Pfizer (2018-2024)
Table 73. Pfizer Recent Developments
Table 74. Teva Basic Information List
Table 75. Teva Description and Business Overview
Table 76. Teva Neuraminidase Inhibitors Drug Products, Services and Solutions
Table 77. Revenue (US$ Million) in Neuraminidase Inhibitors Drug Business of Teva (2018-2024)
Table 78. Teva Recent Developments
Table 79. Bristol-Myers Squibb Basic Information List
Table 80. Bristol-Myers Squibb Description and Business Overview
Table 81. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Products, Services and Solutions
Table 82. Revenue (US$ Million) in Neuraminidase Inhibitors Drug Business of Bristol-Myers Squibb (2018-2024)
Table 83. Bristol-Myers Squibb Recent Developments
Table 84. Sun Pharmaceutical Basic Information List
Table 85. Sun Pharmaceutical Description and Business Overview
Table 86. Sun Pharmaceutical Neuraminidase Inhibitors Drug Products, Services and Solutions
Table 87. Revenue (US$ Million) in Neuraminidase Inhibitors Drug Business of Sun Pharmaceutical (2018-2024)
Table 88. Sun Pharmaceutical Recent Developments
Table 89. North America Neuraminidase Inhibitors Drug Market Size by Country (2018-2024) & (US$ Million)
Table 90. North America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 91. Europe Neuraminidase Inhibitors Drug Market Size by Country (2018-2024) & (US$ Million)
Table 92. Europe Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 93. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 94. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2018-2024) & (US$ Million)
Table 95. Asia-Pacific Neuraminidase Inhibitors Drug Market Size by Region (2024-2029) & (US$ Million)
Table 96. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Region (2018-2024)
Table 97. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Region (2024-2029)
Table 98. Latin America Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 99. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2018-2024) & (US$ Million)
Table 100. Latin America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 101. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 102. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2018-2024) & (US$ Million)
Table 103. Middle East & Africa Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 104. Neuraminidase Inhibitors Drug Market Trends
Table 105. Neuraminidase Inhibitors Drug Market Drivers
Table 106. Neuraminidase Inhibitors Drug Market Challenges
Table 107. Neuraminidase Inhibitors Drug Market Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuraminidase Inhibitors Drug Market Size Year-over-Year 2018-2029 & (US$ Million)
Figure 2. Global Neuraminidase Inhibitors Drug Market Size (US$ Million), 2018 VS 2022 VS 2029
Figure 3. Global Neuraminidase Inhibitors Drug Market Share by Regions: 2022 VS 2029
Figure 4. Global Neuraminidase Inhibitors Drug Forecasted Market Size Share by Region (2024-2029)
Figure 5. North America Neuraminidase Inhibitors Drug Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 6. Europe Neuraminidase Inhibitors Drug Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 7. Asia-Pacific Neuraminidase Inhibitors Drug Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 8. Latin America Neuraminidase Inhibitors Drug Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 9. Middle East & Africa Neuraminidase Inhibitors Drug Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 10. Product Picture of Oseltamivir
Figure 11. Global Oseltamivir Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 12. Product Picture of Zanamivir
Figure 13. Global Zanamivir Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 14. Product Picture of Peramivir
Figure 15. Global Peramivir Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 16. Product Picture of Laninamivir
Figure 17. Global Laninamivir Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 18. Global Neuraminidase Inhibitors Drug Market Size Share by Type: 2022 & 2029
Figure 19. North America Neuraminidase Inhibitors Drug Revenue Market Share by Type (2018-2029)
Figure 20. Europe Neuraminidase Inhibitors Drug Revenue Market Share by Type (2018-2029)
Figure 21. Asia-Pacific Neuraminidase Inhibitors Drug Revenue Market Share by Type (2018-2029)
Figure 22. Latin America Neuraminidase Inhibitors Drug Revenue Market Share by Type (2018-2029)
Figure 23. Middle East and Africa Neuraminidase Inhibitors Drug Revenue Market Share by Type (2018-2029)
Figure 24. Hospital Pharmacy Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 25. Retail Pharmacy Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 26. Online Pharmacy Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 27. Others Market Size (US$ Million) & YoY Growth (2018-2029)
Figure 28. Global Neuraminidase Inhibitors Drug Market Size Share by Application: 2022 & 2029
Figure 29. North America Neuraminidase Inhibitors Drug Revenue Market Share by Application (2018-2029)
Figure 30. Europe Neuraminidase Inhibitors Drug Revenue Market Share by Application (2018-2029)
Figure 31. Asia-Pacific Neuraminidase Inhibitors Drug Revenue Market Share by Application (2018-2029)
Figure 32. Latin America Neuraminidase Inhibitors Drug Revenue Market Share by Application (2018-2029)
Figure 33. Middle East and Africa Neuraminidase Inhibitors Drug Revenue Market Share by Application (2018-2029)
Figure 34. Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 35. Global Top 5 and Top 10 Players Neuraminidase Inhibitors Drug Market Share in 2022
Figure 36. North America Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 37. United States Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 38. Canada Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 39. Germany Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 40. France Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 41. U.K. Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 42. Italy Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 43. Russia Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 44. Nordic Countries Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 45. Asia-Pacific Neuraminidase Inhibitors Drug Market Share by Region (2018-2029)
Figure 46. China Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 47. Japan Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 48. South Korea Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 49. Southeast Asia Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 50. India Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 51. Australia Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 52. Latin America Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 53. Mexico Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 54. Brazil Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 55. Middle East & Africa Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 56. Turkey Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 57. Saudi Arabia Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 58. UAE Neuraminidase Inhibitors Drug Market Size (2018-2029) & (US$ Million)
Figure 59. Bottom-up and Top-down Approaches for This Report